Table 2.

Association Between Zygosity at HLA Class I Loci and Class II Loci and Chronic HBV Infection Among People With a History of HBV Infection in Taiwan

HLA Zygosity	HBsAg Positive, REVEAL-HBV cohort (n = 3416)	HBsAg Negative/Anti-HBc Positive, TWB (n = 6187)	Adjusted OR (95% CI)a
Class I loci
Heterozygous at all loci	2309 (67.6)	4408 (71.2)	Ref.
Homozygous in at least 1 locus	1107 (32.4)	1779 (28.8)	1.00 (.88–1.14)
Number of homozygous
1	786 (23.0)	1290 (20.9)	0.96 (.83–1.12)
2	218 (6.4)	324 (5.2)	1.09 (.84–1.41)
3	103 (3.0)	165 (2.7)	1.14 (.78–1.68)
P trend			.59
HLA-A
Heterozygote	2777 (81.3)	5128 (82.9)	Ref.
Homozygote	639 (18.7)	1059 (17.1)	0.95 (.81–1.11)
HLA-B
Heterozygote	6059 (89.5)	5598 (90.5)	Ref.
Homozygote	357 (10.5)	589 (9.5)	1.08 (.88–1.31)
HLA-C
Heterozygote	2881 (84.3)	5402 (87.3)	Ref.
Homozygote	535 (15.7)	785 (12.7)	1.11 (.93–1.32)
Class II loci
Heterozygous at all loci	1865 (54.6)	4012 (64.8)	Ref.
Homozygous in at least 1 locus	1551 (45.4)	2175 (35.2)	1.36 (1.20–1.54)
Number of homozygous
1	1102 (32.3)	1653 (26.7)	1.27 (1.11–1.46)
2	268 (7.8)	355 (5.7)	1.56 (1.22–1.99)
3	181 (5.3)	167 (2.7)	1.78 (1.28–2.48)
P trend			1.18 × 10–7
HLA-DPB1
Heterozygote	2203 (64.5)	4563 (73.8)	Ref.
Homozygote	1213 (35.5)	1624 (26.2)	1.37 (1.20–1.56)
HLA-DQB1
Heterozygote	2835 (83.0)	5432 (87.8)	Ref.
Homozygote	581 (17.0)	755 (12.2)	1.30 (1.10–1.55)
HLA-DRB1
Heterozygote	3029 (88.7)	5702 (92.2)	Ref.
Homozygote	387 (11.3)	485 (7.8)	1.40 (1.14–1.73)

Data are No. (%).

Abbreviations: CI, confidence interval; HBc, hepatitis B core; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; OR, odds ratio; Ref., reference; REVEAL-HBV, Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-Hepatitis B Virus study; TWB, Taiwan Biobank.

^aAdjusted for sex, age (in categories, 30–39, 40–49, 50–59, 60–79 years), ethnicity, and principal components.